NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)

About NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V. - Ordinary Shares News